Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Sanofi Fails to Block Sale of Taxotere Generics in Australia

Sanofi-Aventis SA failed to block two generic drug manufacturers from selling a copy of the cancer drug Taxotere in Australia, with a federal court judge refusing to bar the sale of the generics.

Judge Jayne Jagot yesterday denied Sanofi’s request for an injunction, clearing the way for Hospira Inc. and Interpharma Ltd. to sell their copies as soon as a patent on Taxotere’s main ingredient docetaxel expires Feb. 6.

Taxotere accounts for 95 percent of Sanofi cancer drug sales in Australia, according to the judge, who wrote “the lost sales represent substantial sums of money.” Sanofi, based in Paris, can be compensated for the lost sales if it’s able to convince a judge at trial that its patent has been infringed, Jagot ruled.

Taxotere, used to treat prostate cancer, generated 2.18 billion euros ($3.02 billion) in global sales in 2009 for Sanofi.

Alan Brindell, a spokesman for Sanofi in Australia, didn’t immediately respond to a request for comment left on his office voice mail.

Sanofi waited too long to object to the entry of the generics into the market to be granted a temporary bar on the sale of the copies, Jagot said.

“There has been undue and inadequately explained delay by the Aventis parties,” Jagot wrote in the ruling, released on the court’s website today.

The case is Between Hospira Australia Ltd. and Aventis Pharma SA. NSD 1521/2010. Federal Court of Australia (Sydney).

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.